Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Normally, we would encourage you to maintain a stiff upper lip, since only a short spell must be endured before the end of the week arrives. However, on this side of the pond, a long holiday weekend will soon get under way, so we would like to note that we will return on Monday. Meanwhile, we hope you enjoy yourselves if you are indulging in such holiday traditions. As for now, here are some tidbits to help you along the journey. All best, and see you soon …

A federal jury in Boston found the former chief financial officer of Aveo Pharmaceuticals (AVEO) liable for civil securities fraud for misleading investors about the prospects to win approval of a kidney cancer drug candidate, The Boston Globe writes. David Johnston told investors the drug was moving toward approval, but the FDA told the company it had deep concerns about how a trial had been designed and that comparisons with another medicine on the market were fundamentally flawed. The agency in 2013 rejected an application to approve the medicine.


In a long-awaited move, a federal advisory panel recommended that doctors be encouraged to offer an HIV prevention pill, a step that would quickly expand insurance coverage for a medicine that has been difficult for some people to access due to its cost, STAT reports. Should physicians adopt the recommendation, the medicine may finally fill its potential, which has seen modest uptake due to what patient advocates argue is high cost. Gilead Sciences (GILD), which sells the pill known as PrEP or Truvada, denies its pricing is an impediment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!